OncoCyte Corp: management transactions · United States · SEC (Form 4)

About OncoCyte Corp

OncoCyte Corp (ticker: OCX) is a U.S.-based precision diagnostics company listed on the NASDAQ in the United States. Headquartered in Irvine, California, the company develops and commercializes molecular diagnostic tests designed to provide physicians with actionable information at critical decision points across the patient-care pathway, with an emphasis on oncology and transplantation. Its business model is more aligned with specialized diagnostics than with traditional pharmaceuticals, focusing on clinical decision support rather than drug development. From a historical perspective, OncoCyte has been built through a combination of internal development and targeted acquisitions of diagnostic technologies. Company disclosures indicate that the acquisition of Chronix Biomedical expanded its scientific capabilities in circulating biomarkers and cell-free DNA. The company operates under the Oncocyte brand and maintains a meaningful operational footprint in Irvine, along with a CLIA-certified laboratory in Nashville, Tennessee. That regulated laboratory infrastructure is strategically important in the U.S. diagnostics market, where analytical validation, clinical utility, and reimbursement are key determinants of commercial adoption. OncoCyte’s main business lines are now centered on transplant diagnostics and, more broadly, on tests that help classify or monitor patients. The GraftAssure franchise has become the core of the company’s growth narrative: these assays measure donor-derived cell-free DNA (dd-cfDNA) to monitor organ health after transplantation, particularly in kidney transplant settings. The company also retains legacy oncology-related assets, including gene-expression-based tests and tools intended to support treatment decisions. In commercial terms, OncoCyte is targeting specialized, high-value niches where more accurate testing may improve treatment decisions and potentially lower overall care costs. Competitively, OncoCyte operates in a demanding market shaped by larger, better-capitalized molecular diagnostics companies and reference laboratories with broader distribution reach. Its differentiation depends on clinical validation, intellectual property, product specialization, and strategic partnerships. Recent company updates point to a business that is still scaling commercially: in 2025 and 2026, management emphasized progress in broader adoption of GraftAssure and continued execution around transplant-diagnostics expansion. For investors, OncoCyte is therefore a high-risk, innovation-driven diagnostics story, with value creation tied to regulatory milestones, reimbursement progress, and the pace of clinical adoption.